

Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies

Jonathan DePierro, Lauren Lepow, Adriana Feder, and Rachel Yehuda

ABSTRACT

Many biological systems are altered in association with posttraumatic stress disorder (PTSD) and resilience. However, there are only few approved pharmacological treatments for PTSD, and no approved medications to enhance resilience. This article provides a critical review of select neurobiological findings in PTSD and resilience, and also of pharmacologic approaches that have emerged from this work. The medications summarized involve engagement with targets in the adrenergic, hypothalamic-pituitary-adrenal axis, and neuropeptide Y systems. Other highlighted approaches involve the use of ketamine and 3,4-methylenedioxymethamphetamine-assisted psychotherapy, which recently surfaced as promising strategies for PTSD, though the neurobiological mechanisms underlying their actions, including for promoting resilience, are not yet fully understood. The former approaches fall within the broad concept of “rational pharmacotherapy,” in that they attempt to directly target dysregulated systems known to be associated with posttraumatic symptoms. To the extent that use of ketamine and 3,4-methylenedioxymethamphetamine promotes symptom improvement and resilience in PTSD, this provides an opportunity for reverse translation and identification of relevant targets and mechanisms of action through careful study of biological changes resulting from these interventions. Promoting resilience in trauma-exposed individuals may involve more than pharmacologically manipulating dysregulated molecules and pathways associated with developing and sustaining PTSD symptom severity, but also producing a substantial change in mental state that increases the ability to engage with traumatic material in psychotherapy. Neurobiological examination in the context of treatment studies may yield novel targets and promote a greater understanding of mechanisms of recovery from trauma.

Keywords: Glucocorticoids, Ketamine, MDMA, Pharmacotherapy, PTSD, Resilience

<https://doi.org/10.1016/j.biopsych.2019.07.009>

Shortly after the appearance of posttraumatic stress disorder (PTSD) in the psychiatric nosology (1), and again more recently (2), Friedman suggested that optimal pharmacotherapy for PTSD would result from targeting unique features of its pathophysiology. Friedman’s original statement (1) was made when little was known about the biology of PTSD, but many believed that its distinct clinical presentation and relationship to environmental exposure would necessitate novel treatments. As early neurochemical and neuroendocrine findings in PTSD emerged, it seemed reasonable to develop pharmacotherapeutic strategies based on reversing the observed dysregulation.

Despite evidence implicating numerous biological systems in PTSD (3–6), there are few medications with demonstrated efficacy. The lack of pharmacologic strategies following great investment in translational and biological studies is thought by some to constitute a crisis (7). Fortunately, advances in understanding the neurobiology of resilience offered potentially new targets associated with trauma recovery or promotion of posttraumatic growth. These findings include mechanisms involved in brain plasticity and cognition that could be targeted

to lessen the severity of PTSD symptoms and facilitate a change in perspective or meaning (3,4). For the purpose of this review, resilience is defined broadly as the ability to adapt to adversity and trauma (4), ranging from resistance to bouncing back from trauma exposure to recovery from PTSD, the latter often involving restorative/reintegrative processes of healing accomplished via successful treatment (8,9).

Currently approved medications for PTSD are limited to selective serotonin reuptake inhibitors, initially tested because of their effectiveness in depression, and therefore not a reflection of the vision of a rational pharmacotherapy based on a translational model of discovery. Table 1 provides a summary of compounds that have been examined and the targets hypothesized to explain their actions (see Supplement for an elaborated version of the table).

That advances in the neurobiology of PTSD have not led to novel treatment approaches raises questions concerning the extent to which a translational approach that identifies, and then seeks to reverse, perturbed biological systems associated with PTSD symptoms will yield treatments that produce sufficient recovery from the effects of trauma for the majority of

Table 1. Candidate PTSD Pharmacotherapies

Target System	Target Engagement	Rationale for Use in PTSD
Monoaminergic	SSRIs, TCAs, MAOIs, nefazadone, venlafaxine, trazodone, antipsychotics, mirtazapine, bupropion, TNX-102 (115–121)	Treatment of symptoms overlapping with depression; perhaps PTSD involves diminished capacity to downregulate 5-HT1B receptors; alterations of serotonergic receptors in the amygdala; connection of serotonin, trauma, and hippocampal volume
Glutamatergic	D-cycloserine, pregabalin, ketamine, riluzole, nitrous oxide, SNC-102 (73,74,122–126)	Glutamatergic pathway in PTSD still under investigation, but is likely related to the effect of chronic stress on learning and memory; ketamine may rapidly promote neuroplasticity in PTSD
GABAergic	Benzodiazepines, pregnenolone, tiagabine, ganaxolone, topiramate, riluzole, 7-keto DHEA, SNC-102 (126–133)	Symptomatic improvement of anxiety; possible PTSD deficits in GABA signaling
Adrenergic	Clonidine, guanfacine, prazosin, propranolol, yohimbine, nepadstat, doxazosin, 7-keto DHEA (28,30,34,131,134–137)	Central and peripheral adrenergic hypersensitivity and hyperactivity
HPA Axis	Hydrocortisone, mifepristone, GSK561679, neuropeptide Y, 7-keto DHEA, SRX246 (49–52,58,131,138,139)	Major constituent of the neuroendocrine response to acute and chronic stress
Endocannabinoid	CB1 agonists, cannabidiol (140)	Reduction of hyperadrenergic activity with the specific intent of blocking reconsolidation of fear memory; possible prophylactic immediately after trauma
Opiate	Buprenex/vivitrol (141,142)	Observation that patients self-medicate with opioids to alleviate symptoms of hypervigilance and hyperarousal; preclinical data demonstrating improved behavioral responses to stress
Unknown Mechanism	Gabapentin	Often for comorbid/overlapping symptom reduction
Mitochondrial Respiration in Nerve Cells	Methylene blue (143)	Enhance extinction learning
Oxytocin Related and Vasopressinergic	SRX246 and oxytocin (144,145)	Preclinical and preliminary clinical data suggesting that these agents may correct a dysregulation of vasopressin and oxytocin signaling in stress-related illnesses
Substance P/Tachykinin Pathway	Orvepitant, neurokinin 1 antagonists, GR205171 (146)	Substance P/neurokinin 1 involved in experimental models of stress, fear, reward; substance P elevated in PTSD CSF
Nicotinic	BNC210 (147)	Anxiolytic without cognitive or sedating effects of benzodiazepines
Protein Synthesis	Sirolimus (148)	Inhibit mTOR to alter amygdala and hippocampal dendritic arborization during exposure to modify reconsolidation of traumatic memory
Optimizing Psychotherapy	MDMA, hydrocortisone, D-cycloserine, yohimbine (35,122–124)	Psychotherapy is the most effective treatment, so perhaps medications can make the therapy more accessible and the effects more robust and long lasting

5-HT1B, 5-hydroxytryptamine receptor 1B; CB1, cannabinoid receptor type 1; CSF, cerebrospinal fluid; DHEA, dehydroepiandrosterone; GABA, gamma-aminobutyric acid; HPA, hypothalamic-pituitary-adrenal; MAOI, monoamine oxidase inhibitor; MDMA, 3,4-methylenedioxymethamphetamine; mTOR, mammalian target of rapamycin; PTSD, posttraumatic stress disorder; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant.

patients. Traumatic exposures result in not only behavioral symptoms, but also a disruption of the survivor's worldviews, priorities, and interests. Developing this change in outlook might require activating resilience-related pathways that are distinct from those that contribute to behavioral symptoms.

In considering how neuroscience has catalyzed, and will continue to catalyze, treatment development in PTSD, it should be noted that current treatment guidelines (10,11) have uniformly designated psychotherapy, particularly cognitive behavioral therapy (CBT), as a first-line treatment. CBT is thought to be supported by translational models involving fear extinction and may therefore reflect a target-driven treatment for PTSD (12,13). Recent research has demonstrated effects in normalizing disrupted patterns in brain connectivity (14). While questions remain about whether a single course of CBT is sufficient to achieve recovery for survivors with extreme or repeated trauma (15,16), that psychotherapy alters dysregulated biological circuits provides an object lesson for translational neuroscience, inviting inquiry into a broader set of

targets that might work in synergy with pharmacotherapy. Currently, pharmacotherapy is recommended as an adjunct to psychotherapy, or an approach when psychotherapy is not available (10,17), with the caveat that medications constitute “low effect” treatments (11).

In clinical practice, many patients with PTSD are prescribed psychotropic medications without psychotherapy because the patient does not want, failed to respond to, dropped out of, or had adverse reactions to psychotherapy. Physicians often use medications off label and/or prescribe several medications concurrently. Yet, many patients remain chronically symptomatic. The failure to successfully treat PTSD with pharmacotherapy alone may reflect that the ultimate biological targets for PTSD symptom reversal have not been identified, or that clinically relevant subtyping has yet to inform personalized therapeutic options. Target activation with the medication may be enhanced through engagement with the traumatic material. Bringing the traumatic memory into consciousness may even activate similar biological circuits to those targeted by

medications. However, it is not currently known whether pharmacological activation of these same circuits would yield similar effects as psychotherapy (18). Alternatively, medications may activate biological targets that might maximize response to trauma-focused psychotherapy.

This review examines selected molecular and neuroendocrine findings in PTSD and resilience from the perspective of rational pharmacotherapy. It also examines how identification of biological targets may come about using neurobiological analysis of treatments that have not been born from traditional rational pharmacotherapy approaches.

CANDIDATE THERAPEUTIC TARGETS

Adrenergic System

Initial studies in PTSD showed increased sympathetic nervous system (SNS) arousal and elevated basal levels of catecholamines such as norepinephrine (19–22). Furthermore, administration of the α_2 receptor antagonist yohimbine precipitated flashbacks (23). Subsequent studies confirmed central and peripheral noradrenergic system involvement in trauma-related processes, including fear and extinction learning, depression, anxiety, and resilience (22,24).

Medications targeting central and peripheral adrenergic hyperactivity, such as α_2 agonists clonidine and guanfacine, have met limited success (25,26). An exception is the α_1 adrenoreceptor antagonist prazosin, which showed a signal for treatment of nightmares (27). The promising results of initial prazosin trials (28) led to fairly broad use of the drug in the Department of Veterans Affairs and in private settings [e.g., (29)], though a recent large-scale study did not show efficacy for prazosin above placebo in moderating nightmare severity (30). The β -adrenergic receptor blocker propranolol has been of interest in the context of blocking the consolidation or reconsolidation of traumatic memories (31). Propranolol decreased fear learning in animals (32), though data regarding its effect on emotional memory in people are less straightforward.

Given the importance of the adrenergic systems in mediating hyperarousal and re-experiencing symptoms in PTSD, as well as fear learning, extinction, and reconsolidation, the lack of a translatable pharmacologic treatment for PTSD based on noradrenergic manipulation has been disappointing. The findings imply that reducing both central and peripheral SNS arousal directly might not be sufficient for promoting recovery; however, it remains plausible that individuals with clear adrenergic dysregulation (33) may benefit from these therapies.

Although medications such as propranolol have not produced a robust treatment signal for treatment or prevention of PTSD (31), they might augment psychotherapy if used prior to reactivation of trauma memories (34). The question that arises is whether exposure therapies are enhanced or disrupted by manipulating arousal or distress at reminders during early phases of treatment. Reducing distress may help patients better access traumatic memories in therapy. However, initial distress might facilitate more powerful extinction or desensitization with subsequent exposures. Indeed, a single dose of yohimbine prior to exposure therapy increased in-session subjective distress and physiological arousal, but produced

lower heart rate reactivity to trauma reminders at 1-week follow up, without influencing PTSD scores (35).

Glucocorticoid System

The hypothalamic-pituitary-adrenal (HPA) axis is the major constituent of the neuroendocrine response to acute and chronic stress and has been well characterized. Cortisol is involved in the regulation and containment of the SNS and parasympathetic responses to stress, both adaptive responses that help the body adapt to a stressor. The autor-regulation of the normal stress response initiated by cortisol (through negative feedback inhibition) helps restore stress-related reactions to baseline after the termination of the acute stressor (36). An efficient negative feedback inhibition (secondary to enhanced glucocorticoid receptor [GR] responsiveness) results in attenuated cortisol elevations in response to stress, thereby increasing the body's exposure to its own catecholamines (37).

When HPA axis dysregulation has been noted in chronic PTSD, it is generally altered in a paradoxical direction with elevated corticotropin-releasing hormone levels despite decreased levels of cortisol. The cortisol response to dexamethasone is greater, reflecting enhanced responsiveness of GR in the pituitary (37–40). This profile differs from that observed in depression, in which both elevated corticotropin-releasing hormone and cortisol levels are present with diminished GR responsiveness (37). Differences in cortisol signaling in PTSD also contribute to abnormally reduced exposure of some afferent pathways to cortisol, thereby contributing to increased sympathetic activation (41–43). As catecholamines facilitate the consolidation of memories (44) and cortisol facilitates extinction and interferes with fear memory reconsolidation (45), suboptimal levels of cortisol in the presence of greater SNS activation might facilitate the formation of the durable traumatic memories that characterize PTSD (46).

Attempts to utilize HPA axis interventions in chronic PTSD are challenging because long-term administration of steroids in nonendocrine conditions can have unintended consequences and is ill-advised when hormone levels are in the endocrinologically normal range. Ideal HPA interventions would be short term and designed to recalibrate a dysregulated feedback loop. However, such strategies have not yielded powerful results to date. A multisite phase II randomized clinical trial of the GR antagonist mifepristone comprising a 600-mg daily dose for 1 week indicated no overall advantage over placebo for PTSD symptoms (47). Subgroup analysis indicated that combat veterans without a history of mild traumatic brain injury experienced significant symptom improvements with mifepristone. Dunlop *et al.* (48) showed no improvement in PTSD in a placebo-controlled trial of a corticotropin-releasing hormone type 1 receptor antagonist. While targeting the HPA axis would appear to constitute a rational pharmacotherapy approach based on the unique alterations in PTSD, glucocorticoid-based treatments have not yielded significant treatment gains in chronic PTSD.

The HPA axis may, however, be a target for secondary PTSD prevention. A serendipitous observation that hydrocortisone as part of standard treatment following septic shock improved mental health outcomes (49) led to a controlled trial

demonstrating that corticosteroids administered following major surgery resulted in higher quality of life 6 months later (50). Based on the idea that lower cortisol levels at the time of trauma exposure might facilitate SNS hyperactivity and lead to intrusive, traumatic memories, this strategy of glucocorticoid administration during the “golden hours” following trauma was used to identify its role in PTSD prevention (51,52). A Cochrane review (53) concluded that hydrocortisone treatment in the acute aftermath of trauma is the only current preventive pharmacological agent with a convincing evidence base. If replicated, this treatment would constitute rational psychopharmacology for PTSD prophylaxis.

Augmentation of psychotherapy with hydrocortisone has also been examined to enhance reconsolidation of emotional memories working synergistically with prolonged exposure, a cognitive behavioral therapy. An initial case report found greater improvement in PTSD symptoms postexposure treatment relative to placebo (54), and a follow-up placebo-controlled study observed that responders to hydrocortisone augmentation had greater GR sensitivity at treatment initiation (55). Hydrocortisone administered immediately following an exposure therapy session resulted in lower avoidance and numbing symptoms 1 week later, when participants were experimentally presented with their trauma narratives (56). Interestingly, the synthetic glucocorticoid dexamethasone was found to have no added benefit in virtual reality-based PTSD treatment in veterans and was associated with greater dropout relative to placebo (57). Unlike hydrocortisone, dexamethasone does not cross the blood-brain barrier; thus, while dexamethasone reduces endogenous cortisol via negative inhibition at the pituitary, it may amplify low cortisol effects in the brain in a pathophysiological direction.

Neuropeptide Y

Laboratory work since the 1990s has implicated neuropeptide Y (NPY) in modulating stress responses [for review, see Schmeltzer *et al.* (58)]. NPY, a neuropeptide implicated in anxiety-related behavior, regulates HPA axis activity by stimulating release of adrenocorticotrophic hormone and corticosterone and decreases SNS activity through inhibition of norepinephrine release from sympathetic noradrenergic neurons. An initial study conducted in soldiers during survival school training demonstrated increases in plasma NPY levels following uncontrollable stress in Special Forces soldiers, who are considered to be more resilient, than in non-Special Forces soldiers. Higher NPY levels during stress were associated with better behavioral performance scores, lower self-reported dissociation, and higher cortisol responses, suggesting that NPY might be associated with resilience during uncontrollable stress (59). Other studies demonstrated lower plasma NPY levels and blunted NPY response to yohimbine in men with combat-related PTSD (60) and higher plasma NPY levels in combat-exposed veterans who recovered from PTSD, compared with those who never had it (61). Veterans with chronic PTSD were also found to have lower concentrations of cerebrospinal fluid NPY relative to healthy control subjects (62). Moreover, individuals with the low NPY expression diplotype evidenced greater amygdala reactivity to fearful faces (63).

A recent small-scale study tested ascending doses of intranasal NPY administration in a crossover placebo-controlled study and found that higher doses (e.g., 9.6 mg) were associated with greater reductions in self-reported anxiety following a trauma script symptom provocation (64). Additional studies are needed to evaluate the full potential of NPY for the treatment or prevention of PTSD. If effective, this treatment would also constitute a rational psychopharmacological approach.

Promising Pharmacologic Strategies Offering an Opportunity for Reverse Translation

Ketamine. Ketamine, a glutamate *N*-methyl-D-aspartate receptor antagonist, was in use in 1970 as an anesthetic but became a drug of abuse owing to its dissociative effects (65). It was subsequently observed to relieve depressive symptoms and later demonstrated to be effective for treatment-resistant depression (66–68). Recently, its S(+) enantiomer esketamine administered intranasally received Food and Drug Administration approval for treatment-resistant depression in conjunction with an oral antidepressant (69). Ketamine has very rapid effects, acting through glutamatergic signaling as well as secondary brain-derived neurotrophic factor, mammalian target of rapamycin, and other signaling pathways (70). At the time its antidepressant effects were noted, the potential involvement of the glutamate system in depression was a nascent idea. However, because the drug was already a Food and Drug Administration–approved compound, research could begin prior to a more complete understanding of the drug’s neurobiological mechanism(s) of action. Ketamine’s actions have led to a greater understanding of the role of glutamatergic function in psychiatric disorders (71).

The initial success of ketamine in treatment-resistant depression trials prompted an interest in ketamine’s potential rapid acting effects in PTSD (72–74). A controlled trial using single-dose intravenous ketamine (vs. midazolam) demonstrated rapid reduction in PTSD and depressive symptom severity at 24 hours postinfusion (74). Coupled with findings from structural and functional imaging studies, these data have contributed to the hypothesis that PTSD is a “synaptic disconnection syndrome” (75). Ketamine has been found to increase prefrontal connectivity in depressed patients (76,77)—a circuit thought to be disrupted in PTSD (78,79). The initial promising findings for PTSD require replication, and ongoing trials are in progress (73) to determine the duration of potential symptom improvement and maintenance with repeated infusions. If successful, this represents an exciting, contrasting paradigm for drug development, in which medications with promise might lead to a greater understanding of disease pathophysiology.

Treatment with rapid-acting medications such as ketamine has prompted the investigation of the role of plasticity in the pathophysiology and treatment of PTSD (75). PTSD-associated synaptic loss, linked to diminished plasticity, has been identified in human postmortem tissue (80) and suggested by imaging results [reviewed in Krystal *et al.* (75)]. Previously discussed mechanisms in PTSD such as changes in GR signaling, inflammatory changes, and alterations in cortisol level also affect synaptic loss, suggesting downstream effects

of these disparate systems to a potential final common pathway (75). Therapeutic effects may occur via restoring synaptic connectivity by increasing dendritic spines as evidenced by the observation that ketamine rapidly reversed the synaptic spine deficits caused by chronic stress in the prefrontal cortex in animal studies (81).

A state of induced plasticity, known as iPlasticity (82), may allow for environmental stimuli such as rehabilitation to reorganize pathological networks and may be a key factor in resilience. Early data postulates that serotonergic psychedelics, which have been referred to as “psychoplastogens,” increase neurogenesis, spinogenesis, and synaptogenesis to a comparable or greater degree than ketamine (83). The effect is believed to be mediated by engagement of serotonergic 2A receptors (84), and there are many examples to suggest that increasing serotonin levels affects one’s sensitivity to the environment (85). An important future direction of treatment may involve catalyzing elements of psychotherapy by creating optimal neural conditions—in this case, perhaps reopening a critical period of plasticity during which relevant circuits can be engaged and manipulated via targeted psychological rehabilitation (86).

3,4-Methylenedioxymethamphetamine–Assisted Psychotherapy. 3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative belonging to a class of agents known as psychedelics, which promote feelings of euphoria, empathy, and trust (87–89). MDMA was first synthesized in 1912, and its ability to catalyze psychotherapy by rapid promotion of introspection and insight in a therapeutic setting was observed anecdotally by the late 1970s (90,91). MDMA increases release of presynaptic serotonin and increases activity at serotonin 2A receptors; is also increases peripheral dopamine (92), cortisol and prolactin (88), and oxytocin (88,93). Like ketamine, MDMA became popular as a recreational substance (“ecstasy”). Unlike ketamine, MDMA was classified as a Schedule I drug in 1986 and remained that way, effectively blocking investigation into its clinical safety and efficacy for psychiatric conditions until recently (94,95). MDMA was granted Investigational New Drug status for PTSD in 2004 in the United States after extensive advocacy efforts (95), and was designated by the Food and Drug Administration as a breakthrough therapy for PTSD in 2017.

Phase II trials for MDMA-assisted psychotherapy have yielded promising results for PTSD. An initial trial in patients with treatment-resistant PTSD with a mean duration of 20 years demonstrated an effect size of 1.24 and 83% remission rate (96). Long-term follow-up indicated that these responses were durable several years after original dosing (97). The positive and long-term effects were replicated in several other phase II randomized clinical trials, with remission in treatment-refractory patients varying somewhat by dose, but at its most conservative, 54% (vs. 23% placebo) of patients achieved full remission. Though initial trials with multiple groups in several countries have been promising, the efficacy of MDMA-assisted psychotherapy will depend on the outcome of phase III trials currently underway (98). Similar to ketamine, effect sizes may also not be comparable to other treatments, given that a truly blinded placebo-control condition is difficult given the strong,

generally euphoric effects of MDMA; therefore, comparison to a current approved treatment will ultimately prove informative.

Importantly, and unlike ketamine, treatment with MDMA occurs in the context of a psychotherapy protocol in which patients receive several preparation sessions prior to 2 or 3 full sessions with MDMA, and several integration sessions following each session. The sessions with MDMA last about 8 hours and are facilitated by 2 co-therapists who provide psychotherapy as traumatic material is brought forward by the patient. The patient is generally not distressed, but rather is relaxed and introspective. In all, patients receive about 40 hours of psychotherapy with 2 providers simultaneously, which is twice the length of a course of CBT (98).

Initial concerns were raised about the potential for abuse of a recreational drug and the possibility of use-related cognitive impairment (99–101). However, the study finding dopaminergic neurotoxicity in nonhuman primates presumed to have been given MDMA was retracted when it was discovered that the animals were mistakenly given methamphetamine (102). While safety data are important, there are significant limitations in comparing adverse events in those reporting recreational use versus those enrolled in a controlled clinical trial. For example, adverse cognitive effects noted in recreational users report lifetime dosages 20× to 400× that of the cumulative dose used in treatment (103). In contrast, no cognitive impairments were noted in the phase II trials that featured neuropsychological assessments (98). Safety monitoring and restricted access to medications will need to continue in the early stages of clinical use. The careful psychotherapy protocol in association with MDMA are essential to the actions of this treatment and is absent in recreational use. Nonetheless, it is important to consider the potential for misuse of any medication that has rapid-acting effects in improving mood states.

Like ketamine, MDMA-assisted psychotherapy was not designed to engage a target in a mechanistic neural pathway, but rather its positive effect on patients suffering from PTSD has warranted scientific inquiry into its neural and molecular actions. MDMA may work by creating the optimal neuronal conditions to establish a corrective event as significant as the trauma. A recent preclinical study (104) elucidated a potential pathway involving reopening of the critical period of social learning via oxytocin-dependent induction of long-term depression in the nucleus accumbens, but this needs follow-up study in humans. It has recently been suggested that MDMA assists the psychotherapeutic process by reducing activation in brain regions implicated in the expression of fear- and anxiety-related behaviors (amygdala and insula) and increasing connectivity between the amygdala and hippocampus. In this manner, MDMA may allow for reprocessing of traumatic memories and emotional engagement with therapeutic processes in an optimized physical and mental state (105). Phenomenologically, MDMA seems to optimize important components of psychotherapy: it reportedly facilitates an optimal level of arousal while processing traumatic memories, increases empathy toward self, catalyzes therapeutic alliance and trust between the patient and the provider, and promotes feelings of and desire for connectedness. These factors may allow the patient to engage and process trauma with self-compassion and without feeling overwhelmed (106).

DISCUSSION AND FUTURE CONSIDERATIONS

A major purpose of researching the pathophysiology of PTSD is to identify biological dysregulations that might be the proximal cause of symptoms. However, targeting pathways or systems that are altered in PTSD has not led to drastic reductions in PTSD symptoms [e.g., (30,31,107)]. Rather, among the most promising strategies for PTSD are ketamine and MDMA, compounds that have not emerged from basic research. If they are consistently effective in clinical trials, these strategies will prompt laboratory studies of their mechanism of action that may contribute to a more complete picture of risk and resilience pathways.

The limited success of approaches thus far may reflect that biological findings consistently observed in association with PTSD may not represent key drivers of symptoms, or limitations in methods of observation, including that many biological studies have been performed on blood samples alone, owing to the unavailability of brain tissue. A limited number of studies have simultaneously evaluated multiple putative biological pathways [e.g., (108–110)], yet PTSD appears to represent a multisystem, multilevel condition affecting metabolic, neurocognitive, cardiac, immune, and brain function. This observation complicates the process of target identification and drug development.

One of the challenges in evaluating the literature on pharmacological strategies is that no single drug has emerged as efficacious for PTSD, though many provide symptom relief in certain patients. It may be that pharmacogenomic strategies may identify PTSD biological subtypes that preferentially respond to specific pharmacologic targets (111,112). Alternatively, biological mechanisms associated with recovery or resilience might be engaged by psychotherapy and/or facilitated by pharmacological strategies that leverage the strengths of both modalities when used in an integrated manner. Evaluating biological changes before and after such approaches may help understand their mechanisms of action.

CONCLUSIONS

The search for druggable targets based on putative pathophysiology or biological differences between PTSD and resilient persons has not yet yielded broadly applicable pharmacological strategies for this disorder. This review has focused on targets drawn from candidate-driven approaches to understanding biological alterations in PTSD; thus, there are still potential targets to be identified using genome-wide systems biology and computational neuroscience approaches (5). Successful pharmacotherapeutic strategies may depend on identifying biological or clinical subgroups of PTSD and/or symptom configuration characteristics of specific stages of illness or PTSD phenotypes (113,114), factors that may not have been fully considered in existing randomized clinical trials. Alternatively, approaches to drug development that are borne from understanding the biological correlates of recovery following psychotherapy or pharmacological augmentation of psychotherapy may be needed to identify mechanism associated with successful processing and integration of traumatic material.

The lack of success of strategies based on a one-size-fits-all rational pharmacotherapy justifies a re-evaluation of this approach with the aim of identifying better methods of target

detection and more viable compounds or treatments. It is appropriate to learn from promising strategies discovered serendipitously; this can be accomplished using biological psychiatry approaches in reverse translational models to understand the neurobiological mechanisms involved in recovery. Indeed, despite having a clear etiological agent—exposure to an event—PTSD has proven to be an exceedingly heterogeneous and complex condition, and one that is not easily addressed by a single strategy, though treatment is often facilitated by combining modalities, including pharmacotherapy and psychotherapy. Therefore, it is worth considering biological mechanisms that might temporarily alter one's mental state to permit more effective trauma processing. The opportunity to examine the meaning of traumatic life events under the influence of such medications while being guided by skilled psychotherapists may constitute a true personalized medicine strategy for PTSD.

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health Grant Nos. U01-OH10729 (to AF) and U01-OH011473 (to AF), a Brain & Behavior Research Foundation NARSAD Independent Investigator Award, U.S. Department of Veterans Affairs Grant No. 5I01CX001219 (to RY), and the U.S. Department of Defense Grant Nos. W81XWH1510706 (to RY) and W81XWH1120223 (to RY).

We thank Heather Bader and Migle Staniskyte for technical assistance.

AF is named co-inventor on a patent application in the United States, and several issued patents outside the U.S. filed by the Icahn School of Medicine at Mount Sinai related to the use of ketamine for the treatment of posttraumatic stress disorder. This intellectual property has not been licensed. RY is listed as co-inventor on a U.S. patent pertaining to genetic testing in posttraumatic stress disorder. All other authors report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Department of Psychiatry (JD, LL, AF, RY), Icahn School of Medicine at Mount Sinai, New York; and Department of Psychiatry (RY), James J. Peters Veterans Affairs Medical Center, Bronx, New York.

Address correspondence to Rachel Yehuda, Ph.D., Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1230, New York, NY 10029; E-mail: rachel.yehuda@va.gov.

Received Mar 29, 2019; revised Jul 8, 2019; accepted Jul 16, 2019.

Supplementary material cited in this article is available online at <https://doi.org/10.1016/j.biopsych.2019.07.009>.

REFERENCES

1. Friedman MJ (1988): Toward rational pharmacotherapy for post-traumatic stress disorder: An interim report. *Am J Psychiatry* 145:281–285.
2. Friedman MJ (2013): Toward rational pharmacotherapy for post-traumatic stress disorder: Reprise. *Am J Psychiatry* 170:944–946.
3. Feder A, Nestler EJ, Charney DS (2009): Psychobiology and molecular genetics of resilience. *Nat Rev Neurosci* 10:446–457.
4. Horn SR, Feder A (2018): Understanding resilience and preventing and treating PTSD. *Harv Rev Psychiatry* 26:158–174.
5. Neylan TC, Schadt EE, Yehuda R (2014): Biomarkers for combat-related PTSD: Focus on molecular networks from high-dimensional data. *Eur J Psychotraumatol* 5:23938.
6. Russo SJ, Murrough JW, Han M-H, Charney DS, Nestler EJ (2012): Neurobiology of resilience. *Nat Neurosci* 15:1475.
7. Krystal JH, Davis LL, Neylan TC, Raskind MA, Schnurr PP, Stein MB, et al. (2017): It is time to address the crisis in the pharmacotherapy of

- posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group. *Biol Psychiatry* 82:e51–e59.
8. Southwick SM, Bonanno GA, Masten AS, Panter-Brick C, Yehuda R (2014): Resilience definitions, theory, and challenges: Interdisciplinary perspectives. *Eur J Psychotraumatol* 5:25338.
9. Harney PA (2007): Resilience processes in context: Contributions and implications of Bronfenbrenner's person-process-context model. *J Aggress Maltreat Trauma* 14:73–87.
10. Management of Posttraumatic Stress Disorder Work Group (2017): VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Washington, DC: Department of Veterans Affairs/Department of Defense.
11. ISTSS Guidelines Committee. Posttraumatic Stress Disorder Prevention and Treatment Guidelines: Methodology and Recommendations. Available at: http://www.istss.org/getattachment/Treating-Trauma/New-ISTSS-Prevention-and-Treatment-Guidelines/ISTSS_PreventionTreatmentGuidelines_FNL.pdf.aspx. Accessed December 23, 2018.
12. Malejko K, Abler B, Plener PL, Straub J (2017): Neural correlates of psychotherapeutic treatment of post-traumatic stress disorder: A systematic literature review. *Front Psychiatry* 8:85.
13. VanElzakker MB, Dahlgren MK, Davis FC, Dubois S, Shin LM (2014): From Pavlov to PTSD: The extinction of conditioned fear in rodents, humans, and anxiety disorders. *Neurobiol Learn Mem* 113:3–18.
14. Abdallah CG, Averill CL, Ramage AE, Averill LA, Alkin E, Nemati S, et al. (2019): Reduced salience and enhanced central executive connectivity following PTSD treatment. *Chronic Stress* 3: 2470547019838971.
15. Yehuda R, Hoge CW (2016): The meaning of evidence-based treatments for veterans with posttraumatic stress disorder. *JAMA Psychiatry* 73:433–434.
16. Steenkamp MM (2016): True evidence-based care for posttraumatic stress disorder in military personnel and veterans. *JAMA Psychiatry* 73:431–432.
17. National Institute of Clinical Excellence (2018): Post-traumatic Stress Disorder. London: NICE.
18. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW (2016): Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments. *Depress Anxiety* 33:792–806.
19. Pittman R, Orr S (1990): Twenty-four hour urinary cortisol and catecholamine excretion in combat-related posttraumatic stress disorder. *Biol Psychiatry* 27:245–247.
20. Pitman RK, Orr SP, Forgue DF, de Jong JB, Claiborn JM (1987): Psychophysiological assessment of posttraumatic stress disorder imagery in Vietnam combat veterans. *Arch Gen Psychiatry* 44:970–975.
21. Barkay G, Freedman N, Lester H, Louzoun Y, Sapoznikov D, Luckenbaugh D, et al. (2012): Brain activation and heart rate during script-driven traumatic imagery in PTSD: Preliminary findings. *Psychiatry Res Neuroimaging* 204:155–160.
22. Krystal JH, Neumeister A (2009): Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. *Brain Res* 1293:13–23.
23. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, et al. (1993): Abnormal noradrenergic function in posttraumatic stress disorder. *Arch Gen Psychiatry* 50:266–274.
24. Hendrickson RC, Raskind MA (2016): Noradrenergic dysregulation in the pathophysiology of PTSD. *Exp Neurol* 284:181–195.
25. Davis L, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM (2008): A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. *Psychopharmacol Bull* 41:8–18.
26. Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, et al. (2006): No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. *Am J Psychiatry* 163:2186–2188.
27. Berardis DD, Marini S, Serroni N, Iasevoli F, Tomasetti C, de Bartolomeis A, et al. (2015): Targeting the noradrenergic system in posttraumatic stress disorder: A systematic review and meta-analysis of prazosin trials. *Curr Drug Targets* 16:1094–1106.
28. Singh B, Hughes AJ, Mehta G, Erwin PJ, Parsaik AK (2016): Efficacy of prazosin in posttraumatic stress disorder: A systematic review and meta-analysis. *Prim Care Companion CNS Disord* 18:16r01943.
29. Harpaz-Rotem I, Rosenheck RA (2009): Tracing the flow of knowledge: Geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs. *Arch Gen Psychiatry* 66:417–421.
30. Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. (2018): Trial of prazosin for post-traumatic stress disorder in military veterans. *N Engl J Med* 378:507–517.
31. Argolo FC, Cavalcanti-Ribeiro P, Netto LR, Quarantini LC (2015): Prevention of posttraumatic stress disorder with propranolol: A meta-analytic review. *J Psychosom Res* 79:89–93.
32. Rodriguez-Romaguera J, Sotres-Bayon F, Mueller D, Quirk GJ (2009): Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction. *Biol Psychiatry* 65:887–892.
33. Friedman MJ, Bernardy NC (2017): Considering future pharmacotherapy for PTSD. *Neurosci Lett* 649:181–185.
34. Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK (2018): Reduction of PTSD symptoms with pre-reactivation propranolol therapy: A randomized controlled trial. *Am J Psychiatry* 175:427–433.
35. Tuerk PW, Wangelin BC, Powers MB, Smits JA, Acierio R, Myers US, et al. (2018): Augmenting treatment efficiency in exposure therapy for PTSD: A randomized double-blind placebo-controlled trial of yohimbine HCl. *Cogn Behav Ther* 47:351–371.
36. Yehuda R, LeDoux J (2007): Response variation following trauma: A translational neuroscience approach to understanding PTSD. *Neuron* 56:19–32.
37. Yehuda R (2018): Neuroendocrinology of PTSD. In: Nemeroff CB, Marmar CR, editors. *Post-traumatic Stress Disorder*. New York: Oxford, 353–374.
38. Yehuda R, Halligan SL, Grossman R, Golier JA, Wong C (2002): The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder. *Biol Psychiatry* 52:393–403.
39. Duval F, Crocq M-A, Guillon M-S, Mokrani M-C, Monreal J, Bailey P, et al. (2004): Increased adrenocorticotropin suppression following dexamethasone administration in sexually abused adolescents with posttraumatic stress disorder. *Psychoneuroendocrinology* 29:1281–1289.
40. Yehuda R, Southwick SM, Krystal JH, Bremner D, Charney DS, Mason JW (1993): Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. *Am J Psychiatry* 150:83–86.
41. Yehuda R, Hoge CW, McFarlane AC, Vermetten E, Lanius RA, Nievergelt CM, et al. (2015): Post-traumatic stress disorder. *Nat Rev Dis Primers* 1:15057.
42. Daskalakis NP, McGill MA, Lehrner A, Yehuda R (2016): Endocrine aspects of PTSD: Hypothalamic-pituitary-adrenal (HPA) axis and beyond. In: Martin CR, Preedy VR, Patel VB, editors. *Comprehensive Guide to Post-Traumatic Stress Disorders*. Cham, Switzerland: Springer International, 245–260.
43. Yehuda R, Golier J (2009): Is there a rationale for cortisol-based treatments for PTSD? *Exp Rev Neurother* 9:1113–1115.
44. Schwabe L, Joëls M, Roozendaal B, Wolf OT, Oitzl MS (2012): Stress effects on memory: An update and integration. *Neurosci Biobehav Rev* 36:1740–1749.
45. de Quervain D, Schwabe L, Roozendaal B (2017): Stress, glucocorticoids and memory: Implications for treating fear-related disorders. *Nat Rev Neurosci* 18:7–19.
46. Yehuda R (2002): Post-traumatic stress disorder. *N Engl J Med* 346:108–114.
47. Golier JA, Yehuda R, Baker D (2017): A randomized clinical trial of a glucocorticoid receptor antagonist in PTSD. *Psychoneuroendocrinology* 83:87.
48. Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, et al. (2017): Corticotropin-releasing factor receptor 1 antagonism is

- ineffective for women with posttraumatic stress disorder. *Biol Psychiatry* 82:866–874.
49. Schelling G, Stoll C, Kapfhammer H-P, Rothenhäusler H-B, Krauseneck T, Durst K, *et al.* (1999): The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. *Crit Care Med* 27:2678–2683.
50. Schelling G, Roozendaal B, Krauseneck T, Schmoelz M, De Quervain D, Briegel J (2006): Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery. *Ann N Y Acad Sci* 1071:46–53.
51. Zohar J, Yahalom H, Kozlovsky N, Cwikel-Hamzany S, Matar MA, Kaplan Z, *et al.* (2013): High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies. *Eur Neuropsychopharmacol* 21:796–809.
52. Delahanty DL, Gabert-Quillen C, Ostrowski SA, Nugent NR, Fischer B, Morris A, *et al.* (2013): The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: A randomized trial. *CNS Spectr* 18:103–111.
53. Amos T, Stein DJ, Ipser JC (2014): Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). *Cochrane Database Syst Rev* 7:CD006239.
54. Yehuda R, Bierer L, Pratchett L, Malowney M (2010): Glucocorticoid augmentation of prolonged exposure therapy: Rationale and case report. *Eur J Psychotraum* 1:5643.
55. Yehuda R, Bierer LM, Pratchett LC, Lehrner A, Koch EC, Van Manen JA, *et al.* (2015): Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: Randomized trial showing improved treatment retention and outcome. *Psychoneuroendocrinology* 51:589–597.
56. Suris A, North C, Adinoff B, Powell CM, Greene R (2010): Effects of exogenous glucocorticoid on combat-related PTSD symptoms. *Ann Clin Psychiatry* 22:274–279.
57. Maples-Keller JL, Jovanovic T, Dunlop BW, Rauch S, Yasinski C, Michopoulos V, *et al.* (2019): When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates. *J Anxiety Disord* 61:89–97.
58. Schmeltzer SN, Herman JP, Sah R (2016): Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): A translational update. *Exp Neurol* 284:196–210.
59. Morgan CA III, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, *et al.* (2000): Plasma neuropeptide-Y concentrations in humans exposed to military survival training. *Biol Psychiatry* 47:902–909.
60. Rasmusson AM, Hauger RL, Morgan CA III, Bremner JD, Charney DS, Southwick SM (2000): Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. *Biol Psychiatry* 47:526–539.
61. Yehuda R, Brand S, Yang R-K (2006): Plasma neuropeptide Y concentrations in combat exposed veterans: Relationship to trauma exposure, recovery from PTSD, and coping. *Biol Psychiatry* 59:660–663.
62. Sah R, Ekhtor NN, Strawn JR, Sallee FR, Baker DG, Horn PS, *et al.* (2009): Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. *Biol Psychiatry* 66:705–707.
63. Zhou Z, Zhu G, Hariri AR, Enoch M-A, Scott D, Sinha R, *et al.* (2008): Genetic variation in human NPY expression affects stress response and emotion. *Nature* 452:997–1001.
64. Sayed S, Van Dam NT, Horn SR, Kautz MM, Parides M, Costi S, *et al.* (2017): A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. *Int J Neuropsychopharmacol* 21:3–11.
65. Liu Y, Lin D, Wu B, Zhou W (2016): Ketamine abuse potential and use disorder. *Brain Res Bull* 126:68–73.
66. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, *et al.* (2000): Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 47:351–354.
67. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, *et al.* (2006): A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry* 63:856–864.
68. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, *et al.* (2013): Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. *Am J Psychiatry* 170:1134–1142.
69. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, *et al.* (2018): Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. *JAMA Psychiatry* 75:139–148.
70. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, *et al.* (2013): Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. *Biol Psychiatry* 74:250–256.
71. Abdallah CG, Sanacora G, Duman RS, Krystal JH (2018): The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? *Pharmacol Ther* 190:148–158.
72. Bermudo-Soriano CR, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E (2012): New perspectives in glutamate and anxiety. *Pharmacol Biochem Behav* 100:752–774.
73. Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, *et al.* (2019): Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. *Contemp Clin Trials* 81:11–18.
74. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, *et al.* (2014): Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. *JAMA Psychiatry* 71:681–688.
75. Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, *et al.* (2017): Synaptic loss and the pathophysiology of PTSD: Implications for ketamine as a prototype novel therapeutic. *Curr Psychiatry Rep* 19:74.
76. Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, *et al.* (2017): Ketamine treatment and global brain connectivity in major depression. *Neuropsychopharmacology* 42:1210–1219.
77. Abdallah CG, Dutta A, Averill CL, McKie S, Akiki TJ, Averill LA, *et al.* (2018): Ketamine, but not the NMDAR antagonist lanicemine, increases prefrontal global connectivity in depressed patients. *Chronic Stress* 2:2470547018796102.
78. Clausen AN, Francisco AJ, Thelen J, Bruce J, Martin LE, McDowd J, *et al.* (2017): PTSD and cognitive symptoms relate to inhibition-related prefrontal activation and functional connectivity. *Depress Anxiety* 34:427–436.
79. Stevens JS, Jovanovic T, Fani N, Ely TD, Glover EM, Bradley B, *et al.* (2013): Disrupted amygdala-prefrontal functional connectivity in civilian women with posttraumatic stress disorder. *J Psychiatr Res* 47:1469–1478.
80. Young KA, Thompson PM, Cruz DA, Williamson DE, Seimon LD (2015): BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls. *Neurobiol Stress* 2:67–72.
81. Duman RS (2014): Neurobiology of stress, depression, and rapid acting antidepressants: Remodeling synaptic connections. *Depress Anxiety* 31:291–296.
82. Castrén E, Antila H (2017): Neuronal plasticity and neurotrophic factors in drug responses. *Mol Psychiatry* 22:1085–1095.
83. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, *et al.* (2018): Psychedelics promote structural and functional neural plasticity. *Cell Rep* 23:3170–3182.
84. Carhart-Harris RL, Goodwin GM (2017): The therapeutic potential of psychedelic drugs: Past, present, and future. *Neuropsychopharmacology* 42:2105–2113.
85. Branchi I (2011): The double edged sword of neural plasticity: Increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. *Psychoneuroendocrinology* 36:339–351.
86. Nabel EM, Morishita H (2013): Regulating critical period plasticity: Insight from the visual system to fear circuitry for therapeutic interventions. *Front Psychiatry* 4:146.

87. Sessa B (2015): The ecstatic history of MDMA: From raving highs to saving lives. In: *Breaking Convention Book of Proceedings from the 2013 Conference*. London: Strange Attractor Press, 87–94.
88. Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, *et al.* (2013): MDMA enhances emotional empathy and prosocial behavior. *Soc Cogn Affect Neurosci* 9:1645–1652.
89. Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, *et al.* (2017): Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. *J Psychopharmacol* 31:967–974.
90. Grinspoon L, Bakalar JB (1986): Can drugs be used to enhance the psychotherapeutic process? *Am J Psychother* 40:393–404.
91. Stolaroff MJ (2004): *The Secret Chief Revealed*. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies.
92. Liechti ME, Vollenweider FX (2001): Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. *Hum Psychopharmacol* 16:589–598.
93. Bershad AK, Weafer JJ, Kirkpatrick MG, Wardle MC, Miller MA, de Wit H (2016): Oxytocin receptor gene variation predicts subjective responses to MDMA. *Soc Neurosci* 11:592–599.
94. Sessa B, Nutt DJ (2007): MDMA, politics and medical research: Have we thrown the baby out with the bathwater? *J Psychopharmacol* 21:787–791.
95. Heifets BD, Malenka RC (2016): MDMA as a probe and treatment for social behaviors. *Cell* 166:269–272.
96. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011): The safety and efficacy of $\pm$ 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. *J Psychopharmacol* 25:439–452.
97. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, *et al.* (2013): Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3, 4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. *J Psychopharmacol* 27:28–39.
98. Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, *et al.* (2019): MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials [published online ahead of print May 7]. *Psychopharmacology*.
99. Parrott AC (2014): MDMA is certainly damaging after 25 years of empirical research: A reply and refutation of Doblin *et al.* (2014). *Hum Psychopharmacol* 29:109–119.
100. Murphy PN, Bruno R, Ryland I, Wareing M, Fisk JE, Montgomery C, *et al.* (2012): The effects of 'ecstasy' (MDMA) on visuospatial memory performance: Findings from a systematic review with meta-analyses. *Hum Psychopharmacol* 27:113–138.
101. Doblin R, Greer G, Holland J, Jerome L, Mithoefer MC, Sessa B (2014): A reconsideration and response to Parrott AC (2013): Human psychobiology of MDMA or 'Ecstasy': An overview of 25 years of empirical research. *Hum Psychopharmacol* 29:105–108.
102. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2003): Retraction. *Science* 301:1479.
103. Multidisciplinary Association for Psychedelic Studies (2017): *MDMA Investigational Brochure*. Santa Cruz, CA: MAPS.
104. Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, *et al.* (2019): Oxytocin-dependent reopening of a social reward learning critical period with MDMA. *Nature* 569:116–120.
105. Feduccia AA, Mithoefer MC (2018): MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? *Prog Neuropsychopharmacol Biol Psychiatry* 84:221–228.
106. Mithoefer MC, Grob CS, Brewerton TD (2016): Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. *Lancet Psychiatry* 3:481–488.
107. Murrough JW, Charney DS (2017): Corticotropin-releasing factor type 1 receptor antagonists for stress-related disorders: Time to call it quits? *Biol Psychiatry* 82:858–860.
108. Somvanshi PR, Mellon SH, Flory JD, Abu-Amara D, Consortium PSB, Wolkowitz OM, *et al.* (2019): Mechanistic inferences on metabolic dysfunction in PTSD from an integrated model and multi-omic analysis: Role of glucocorticoid receptor sensitivity [published online ahead of print Jul 19]. *Am J Physiol Endocrinol Metab*.
109. Ratanatharathorn A, Boks MP, Maihofer AX, Aiello AE, Amstadter AB, Ashley-Koch AE, *et al.* (2017): Epigenome-wide association of PTSD from heterogeneous cohorts with a common multi-site analysis pipeline. *Am J Med Genet B Neuropsychiatr Genet* 174:619–630.
110. Rauch SA, Simon NM, Kim HM, Acierno R, King AP, Norman SB, *et al.* (2018): Integrating biological treatment mechanisms into randomized clinical trials: Design of PROGRESS (PROlonged Exposure and Sertraline Trial). *Contemp Clin Trials* 64:128–138.
111. Mushtaq D, Ali A, Margoob MA, Murtaza I, Andrade C (2012): Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. *J Affect Disord* 136:955–962.
112. Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Gruenbaum M, *et al.* (2018): Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. *Transl Psychiatry* 8:280.
113. Galatzer-Levy IR, Bryant RA (2013): 636,120 Ways to have post-traumatic stress disorder. *Perspect Psychol Sci* 8:651–662.
114. McFarlane AC, Lawrence-Wood E, Van Hooff M, Malhi GS, Yehuda R (2017): The need to take a staging approach to the biological mechanisms of PTSD and its treatment. *Curr Psychiatry Rep* 19:10.
115. MacNamara A, Rabinak CA, Kennedy AE, Fitzgerald DA, Liberzon I, Stein MB, *et al.* (2016): Emotion regulatory brain function and SSRI treatment in PTSD: Neural correlates and predictors of change. *Neuropsychopharmacology* 41:611–618.
116. Stahl SM (2013): *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. New York: Cambridge University Press.
117. Tonix Pharmaceuticals Holding Corp. Tonmya for PTSD. Available at: <https://www.tonixpharma.com/pipeline/tonmya-for-ptsd>. Accessed December 23, 2018.
118. Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, *et al.* (2003): Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial. *Biol Psychiatry* 53:188–191.
119. Alderman CP, Condon JT, Gilbert AL (2009): An open-label study of mirtazapine as treatment for combat-related PTSD. *Ann Pharmacother* 43:1220–1226.
120. Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG (2017): Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. *Neurosci Lett* 649:147–155.
121. Hidalgo R, Hertzberg M, Mellman T, Petty F, Tucker P, Weisler R, *et al.* (1999): Nefazodone in post-traumatic stress disorder: Results from six open-label trials. *Int Clin Psychopharmacol* 14:61–68.
122. Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS, *et al.* (2014): D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: A pilot randomized clinical trial. *Neuropsychopharmacology* 39:1052–1058.
123. de Kleine RA, Hendriks G-J, Kusters WJ, Broekman TG, van Minnen A (2012): A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. *Biol Psychiatry* 71:962–968.
124. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, *et al.* (2014): A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. *Am J Psychiatry* 171:640–648.
125. Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, *et al.* (2015): Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial. *Biol Psychiatry* 78:10–18.
126. Grant P, Song JY, Swedo SE (2010): Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. *J Child Adolesc Psychopharmacol* 20:309–315.
127. Locci A, Pinna G (2017): Neurosteroid biosynthesis down-regulation and changes in GABAA receptor subunit composition: A biomarker

- axis in stress-induced cognitive and emotional impairment. *Br J Pharmacol* 174:3226–3241.
128. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH (2007): The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. *J Clin Psychopharmacol* 27:85–88.
129. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K (2006): Tiagabine for posttraumatic stress disorder: Effects of open-label and double-blind discontinuation treatment. *Psychopharmacology* 184:21–25.
130. Rasmussen AM, Marx CE, Jain S, Farfel GM, Tsai J, Sun X, *et al.* (2017): A randomized controlled trial of ganaxolone in posttraumatic stress disorder. *Psychopharmacology* 234:2245–2257.
131. Yehuda R, Brand S, Golier J, Yang RK (2006): Clinical correlates of DHEA associated with post-traumatic stress disorder. *Acta Psychiatr Scand* 114:187–193.
132. Boothby LA, Doering PL (2005): Acamprosate for the treatment of alcohol dependence. *Clin Ther* 27:695–714.
133. Witkiewitz K, Saville K, Hamreus K (2012): Acamprosate for treatment of alcohol dependence: Mechanisms, efficacy, and clinical utility. *Ther Clin Risk Manage* 8:45–53.
134. Horrigan JP (1996): Guanfacine for PTSD nightmares. *J Am Acad Child Adolesc Psychiatry* 35:975–976.
135. Harmon RJ, Riggs PD (1996): Clonidine for posttraumatic stress disorder in preschool children. *J Am Acad Child Adolesc Psychiatry* 35:1247–1249.
136. Connor DF, Grasso DJ, Slivinsky MD, Pearson GS, Banga A (2013): An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. *J Child Adolesc Psychopharmacol* 23:244–251.
137. Graham DP, Nielsen DA, Kosten TR, Davis LL, Hamner MB, Makotkine I, *et al.* (2014): Examining the utility of using genotype and functional biology in a clinical pharmacology trial: Pilot testing dopamine β -hydroxylase, norepinephrine, and PTSD. *Psychiatr Genet* 24:181–182.
138. Golier JA, Caramanica K, DeMaria R, Yehuda R (2012): A pilot study of mifepristone in combat-related PTSD. *Depress Res Treat* 2012:393251.
139. Golier JA, Caramanica K, Michaelides AC, Makotkine I, Schmeidler J, Harvey PD, *et al.* (2016): A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. *Psychoneuroendocrinology* 64:22–30.
140. Bitencourt RM, Takahashi RN (2018): Cannabidiol as a Therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. *Front Neurosci* 12:502.
141. Pietrzak RH, Naganawa M, Huang Y, Corsi-Travali S, Zheng M-Q, Stein MB, *et al.* (2014): Association of in vivo κ -opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. *JAMA Psychiatry* 71:1262–1270.
142. Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM (2019): Buprenorphine for the treatment of posttraumatic stress disorder. *Am J Addict* 28:86–91.
143. Zoellner LA, Telch M, Foa EB, Farach FJ, McLean CP, Gallop R, *et al.* (2017): Enhancing extinction learning in posttraumatic stress disorder with brief daily imaginal exposure and methylene blue: A randomized controlled trial. *J Clin Psychiatry* 78:e782–e789.
144. Lee RJ, Coccaro EF, Cremers H, McCarron R, Lu S-F, Brownstein M, *et al.* (2013): A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: An fMRI study. *Front Syst Neurosci* 7:100.
145. Donadon MF, Martin-Santos R, Osório FdL (2018): The associations between oxytocin and trauma in humans: A systematic review. *Front Pharmacol* 9:154.
146. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA, *et al.* (2011): A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. *Eur Neuropsychopharmacol* 21:221–229.
147. Garakani A, Murrough JW, Iosifescu DV (2014): Advances in psychopharmacology for anxiety disorders. *Focus* 12:152–162.
148. Suris A, Smith J, Powell C, North CS (2013): Interfering with the reconsolidation of traumatic memory: Sirolimus as a novel agent for treating veterans with posttraumatic stress disorder. *Ann Clin Psychiatry* 25:33–40.